About: Eptinezumab

Property	Value
dbo:abstract	Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion. Eptinezumab was approved for medical use in the United States in February 2020. (en) L'eptinézumab, commercialisé sous le nom de Vyepti par le groupe Lundbeck, est un anticorps monoclonal IgG1 humanisé, mais non glycosylée, qui se lie au peptide relié au gène de la calcitonine (CGRP) et empêche ainsi son activité biologique. (fr)
dbo:alternativeName	Vyepti (en)
dbo:casNumber	1644539-04-7
dbo:drugbank	DB14040
dbo:fdaUniiCode	8202AY8I7H
dbo:kegg	D11303
dbo:wikiPageExternalLink	https://druginfo.nlm.nih.gov/drugportal/name/eptinezumab
dbo:wikiPageID	50083054 (xsd:integer)
dbo:wikiPageLength	10252 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1102283288 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Experimental_drugs dbr:Calcitonin_gene-related_peptide dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbc:Antimigraine_drugs dbc:Monoclonal_antibodies dbr:Migraine dbr:Medication dbr:Intravenous dbr:CALCA dbr:CALCB
dbp:atcPrefix	N02 (en)
dbp:atcSuffix	CD05 (en)
dbp:c	6352 (xsd:integer)
dbp:casNumber	1644539 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:class	Calcitonin gene-related peptide antagonist (en)
dbp:dailymedid	Eptinezumab (en)
dbp:drugbank	DB14040 (en)
dbp:h	9838 (xsd:integer)
dbp:kegg	D11303 (en)
dbp:legalAu	S4 (en)
dbp:legalCa	Schedule D (en)
dbp:legalEu	Rx-only (en)
dbp:legalUs	Rx-only (en)
dbp:mabType	mab (en)
dbp:n	1694 (xsd:integer)
dbp:o	1992 (xsd:integer)
dbp:pregnancyAu	B1 (en)
dbp:routesOfAdministration	dbr:Intravenous
dbp:s	46 (xsd:integer)
dbp:source	zu (en)
dbp:synonyms	ALD403, eptinezumab-jjmr (en)
dbp:target	dbr:CALCA dbr:CALCB
dbp:tradename	Vyepti (en)
dbp:type	mab (en)
dbp:unii	8202 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems dbt:Analgesic-stub dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_dmy_dates dbt:Fdacite dbt:Triptans dbt:Drugs.com dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Experimental_drugs dbc:Antimigraine_drugs dbc:Monoclonal_antibodies
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion. Eptinezumab was approved for medical use in the United States in February 2020. (en) L'eptinézumab, commercialisé sous le nom de Vyepti par le groupe Lundbeck, est un anticorps monoclonal IgG1 humanisé, mais non glycosylée, qui se lie au peptide relié au gène de la calcitonine (CGRP) et empêche ainsi son activité biologique. (fr)
rdfs:label	Eptinezumab (en) Eptinézumab (fr)
owl:sameAs	yago-res:Eptinezumab wikidata:Eptinezumab dbpedia-fr:Eptinezumab dbpedia-vi:Eptinezumab https://global.dbpedia.org/id/2dAyH
prov:wasDerivedFrom	wikipedia-en:Eptinezumab?oldid=1102283288&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Eptinezumab
is dbo:wikiPageRedirects of	dbr:Eptinezumab-jjmr dbr:ALD403 dbr:Vyepti
is dbo:wikiPageWikiLink of	dbr:Lundbeck dbr:Calcitonin_gene-related_peptide dbr:Calcitonin_gene-related_peptide_receptor_antagonist dbr:Eptinezumab-jjmr dbr:ALD403 dbr:ATC_code_N02 dbr:Migraine dbr:List_of_signaling_peptide/protein_receptor_modulators dbr:List_of_therapeutic_monoclonal_antibodies dbr:Signaling_peptide_receptor dbr:Vyepti
is foaf:primaryTopic of	wikipedia-en:Eptinezumab